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Abstract
Background: HIV-1 infection is associated with various quantitative and qualitative changes 
in haemopoietic cells. Clear distinction between primary myelodysplastic syndrome (MDS) 
and  secondary  dysplasia  may  not  always  be  possible.  Adjunctive  analyses  used  in  the 
diagnosis  of  MDS  include  cytogenetics  and  flow  cytometry  (FCM).  Much  focus  has  been 
placed on establishing FCM guidelines aiding in the diagnosis of MDS, and to distinguish this 
condition from secondary dysplastic changes. One of the parameters often cited is
expression on the granulocyte population, as this marker denotes granulocytic maturation.
Aims: To determine the expression level of CD10 on granulocytes in HIV positive patients.
Methods: In total, 117 HIV-1 positive and 29 HIV
study. Bone marrow aspirate samples were evaluated in terms of morphological abnormality 
as well as CD10 expression on the granulocytic population.
Results: The  average  CD10  expression  among  the  HIV
reduced, at 18.4%, and 113 patients (96.6%) of these patients had expression levels below 
50%. 
Discussion: Disease  conditions  causing  secondary  dysplasia,  especially  HIV
associated  with  a  marked  reduction  in  CD10  expression  on  the  granul
independent  from  the  presence  of  myelodysplastic  features.  This  marker  is  therefore  of 
doubtful significance as a diagnostic tool in distinguishing between primary and secondary 
dysplasia.
; Open Journal System 
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1 infection is associated with various quantitative and qualitative changes 
in haemopoietic cells. Clear distinction between primary myelodysplastic syndrome (MDS) 
and  secondary  dysplasia  may  not  always  be  possible.  Adjunctive  analyses  used  in  the 
gnosis  of  MDS  include  cytogenetics  and  flow  cytometry  (FCM).  Much  focus  has  been 
placed on establishing FCM guidelines aiding in the diagnosis of MDS, and to distinguish this 
condition from secondary dysplastic changes. One of the parameters often cited is
expression on the granulocyte population, as this marker denotes granulocytic maturation.
To determine the expression level of CD10 on granulocytes in HIV positive patients.
1 positive and 29 HIV-1 negative patients were included in this 
study. Bone marrow aspirate samples were evaluated in terms of morphological abnormality 
as well as CD10 expression on the granulocytic population.
The  average  CD10  expression  among  the  HIV-1  positive  patients  were  markedl
reduced, at 18.4%, and 113 patients (96.6%) of these patients had expression levels below 
Disease  conditions  causing  secondary  dysplasia,  especially  HIV
associated  with  a  marked  reduction  in  CD10  expression  on  the  granulocyte  population 
independent  from  the  presence  of  myelodysplastic  features.  This  marker  is  therefore  of 
doubtful significance as a diagnostic tool in distinguishing between primary and secondary 
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1 infection is associated with various quantitative and qualitative changes 
in haemopoietic cells. Clear distinction between primary myelodysplastic syndrome (MDS) 
and  secondary  dysplasia  may  not  always  be  possible.  Adjunctive  analyses  used  in  the 
gnosis  of  MDS  include  cytogenetics  and  flow  cytometry  (FCM).  Much  focus  has  been 
placed on establishing FCM guidelines aiding in the diagnosis of MDS, and to distinguish this 
condition from secondary dysplastic changes. One of the parameters often cited is the CD10 
expression on the granulocyte population, as this marker denotes granulocytic maturation.
To determine the expression level of CD10 on granulocytes in HIV positive patients.
ts were included in this 
study. Bone marrow aspirate samples were evaluated in terms of morphological abnormality 
1  positive  patients  were  markedly 
reduced, at 18.4%, and 113 patients (96.6%) of these patients had expression levels below 
Disease  conditions  causing  secondary  dysplasia,  especially  HIV-1  infection,  is 
ocyte  population 
independent  from  the  presence  of  myelodysplastic  features.  This  marker  is  therefore  of 
doubtful significance as a diagnostic tool in distinguishing between primary and secondary Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
Introduction: Infection  with  the  Human 
Immunodeficiency  Virus  (HIV-1)  is  frequently 
associated  with  haematological  abnormalities,
1,2 
including  cytopaenias
3 and  dysplastic  features.
4,5
The  aetiology  for  these  changes  are  often  multi-
factorial
6 including  features  of  peripheral 
destruction,
3bone marrow suppression due to drugs,
7 opportunistic infection
8 or direct effect of HIV-1 
on bone marrow precursor cells.
9,10 HIV-1 infection 
has  also  been  directly  associated  with
myelosuppression with various possible underlying 
mechanisms  postulated,  including  direct  infection 
of  haemopoietic  progenitor  cells,
26,1 stromal  cell 
functional  impairment,  toxic  effects  of  HIV-1 
proteins  and  alterations  in  the  local  cytokine 
milieu.
1 The presence of dysplastic haemopoiesis in 
the bone marrows of HIV-1 positive patients have 
been well described,
23 however, reports on MDS in 
HIV-1  positive  patients  are  rare.
24,23 Superficially 
these  dysplastic  changes  can  be  morphologically 
similar  to  the  dysplasia  seen  in  primary 
myelodysplasia.
30
The  diagnosis  of  MDS  calls  for 
multidisciplinary  evaluation  of  morphological, 
haematological  and  cytogenetic  findings.
4 As  the 
more sophisticated investigations like cytogenetics 
yields aberrant findings in only about 20 to 70% of 
cases,
11,12 novel methods of diagnosis are constantly 
evaluated.  Recently,  more  emphasis  has  been 
placed  the  use  of  flow  cytometry  (FCM)  in  the 
diagnostic  work-up  of  patients  with  MDS.
27,20  
Decreased  or  absent  CD10  expression  in  the 
granulocyte series has been associated with MDS, 
and has been cited to occur in as much as 45% of 
MDS cases.
16 Use of this marker has been proposed 
as a criterion in either diagnostic scoring systems
4
or as supportive diagnostic criteria.
27,16
However, expression levels of CD10 have not 
been  evaluated  in  various  other  conditions, 
including  known  causes  of  secondary  dysplasia, 
particularly HIV-1 infection.
15 A recent publication 
from  the  European  LeukemiaNet  Working 
Conference
16  re-emphasized  use  of  various 
parameters in the evaluation of patients with MDS, 
in an attempt to establish consensus guidelines in 
the diagnosis of MDS. For this reason, it remains 
imperative to fully understand the effect of various 
conditions on CD10 expression on the granulocyte 
population, as this may impact on future diagnostic 
criteria.
This is the first study to the authors’ knowledge 
to investigate CD10 expression in granulocytic cells 
on  bone  marrow  aspirate  samples  from  HIV-1 
positive  patients  with  non-neoplastic 
haematological disorders. 
Materials and Methods: 
Patient  Population: In  total,  117  HIV-1  positive 
and  29  HIV-1  negative  patients  were  included  in 
this study. None of the HIV-1 positive patients had 
been initiated on highly active antiretroviral therapy 
(HAART) at the time of investigation and were in 
varying  stages  of  HIV-1  disease,  as  reflected  by 
CD4  counts.  The  presence  of  concurrent 
opportunistic infections was not known. Exclusion 
criteria included 1) patients younger than 12 years 
of  age,  2)  a  diagnosis  of  any  haematological 
neoplasm  and  3)  HIV-1  negative  test  (in  the 
negative  control  group)  performed  more  than  12 
months  from  bone  marrow  examination.  Flow 
cytometric  data  as  performed  on  bone  marrow 
aspirates were collected on all cases. None of the 
HIV-1  negative  control  group  was  considered  to
have primary myelodysplasia based on morphology 
or karyotyping.
Bone  Marrow  Morphology: Of  the  117  samples 
included, only 70 included sufficient smear samples 
for evaluation of morphological features. The iron 
stain  was  used  to  evaluate  the  presence  of 
sideroblasts, and quantified as low (less than 20%), 
normal (20 to 30%) or increased (more than 30%), 
as well as the presence of pathologically overloaded 
forms.
Flow  Cytometric  Analysis: All  bone  marrow 
specimens were collected in ethylene-diaminetetra-
acetic  acid  (EDTA)  or  sodium-heparin  tubes  and 
processed  within  24  hours.  The  white  blood  cell 
(WBC)  count  was  determined  using  FLOW-
COUNT,  Beckman-Coulter  (Miami,  USA)  and 
corrected  to  within  the  reference  range  (4-10 
x10
9/L) by either dilution with RPMI or buffy coat 
harvesting  by  density  gradient  extraction.  A  total 
volume of 100 µl of the bone marrow specimen was 
mixed with 2 ml of ammonium chloride to lyse red 
blood  cells.  The  specimen  was  incubated  for  10 
minutes and centrifuged for 10 minute at 2000rpm. 
Viability  was  subsequently  determined  by  using 
propidium  iodide.  Only  specimens  with  a  value 
above 75% viability were used.
According  to  our  laboratory’s  standard 
operating  procedure,  10  µl  of  CD10  monoclonal 
antibody was added to 100 µl of the bone marrow. 
Phycoerythrin  (PE)-CD10  by  Beckman-Coulter 
(Miami,  USA)  was  used.  Three  colour  flow  was 
performed  with  the  Cytomics  FC500  flow Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
Figure 1: Granulocytes defined based on a. Side scatter (SS) versus Forward Scatter (FS) (population A) and b. CD45 versus SS 
(population B).
Figure 2: CD10 expression evaluated by a. CD5 FITC versus CD10-PE and b. CD10-PE versus CD19-ECD. Both sets were gated on 
population A as defined in figure 1, identified as granulocytes. Two discrete populations can be demonstrated in each defined as 
either CD10 positive (population C and I) or negative (populations D and H).
cytometer or XL-MCL, Beckman-Coulter (Miami, 
USA)  equipped  with  a  15-mW  argon  laser 
(excitation  at  488mm).  Antibody  panel  used 
included CD5-Fluorescein isothiocyanate (FITC) vs 
CD10-PE  vs  CD19-PE-Texas  red  (ECD). 
Granulocytes were defined using side scatter versus 
forward scatter (Figure 1a) and CD45 (dim) versus 
side  scatter  (Figure  1b).  CD10  expression  was 
determined  within this  population.  Compensation 
within this gate was performed by also incubating 
cells  with  appropriate  fluorochrome-coupled 
isotype  control  antibodies.The  CD10  expression 
was quantified from the CD5-FITC versus CD10-
PE analysis (Figure 2a) and verified by comparison 
to CD10-PE versus CD19-ECD (Figure 2b). CD10 
PE was used to estimate the total CD10 expression 
of  the  granulocyte  population.  Standardization  of 
instrument electronics was done using Flow Check 
Fluorospheres  calibration  beads  by  Beckman-
Coulter (Miami,  USA)  according  to  the 
manufacturer’s  recommendations.  Compensation 
was  adjusted  using  FITC-CD4/PE-CD8/PerCP-
CD3-stained  cells.  Isotypic  controls  were  used  as 
negative controls to eliminate non-specific binding. 
In  each  cell  preparation,  15  to  30  thousand  total 
events  were  collected.  Data  were  analyzed  with Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
CXP  cytometer  software,  Beckman-Coulter 
(Miami,  USA)  gating  the  total  leukocyte 
population. 
Table 1. Baseline demographic and results of study population
Variable
Study population
n=148
HIV-1 positive 
patients
HIV-1 negative 
patients
n=117 n=29
Age (in years) 37 (23-77) 42 (12-85)
Average CD4 
count  129±151 N/A
Average CD10%  
expression* 18.40% 37.10%
Number of 
subjects  with 
CD10% 
expression* <50%
133 (96.6%) 22 (75.9%)
* CD10% expression on granulocyte population 
Results: 
Patient  population: Ages  for  the  patients  varied 
from 23 to 77 years (mean age of 37 years) for the 
HIV-1 positive patients and 12 to 85 years (mean 
age  of  42  years)  for  the  HIV-1  negative  patient 
group (Table 1). Although not HIV-1 infected, the 
latter  group  had  various  underlying  medical 
conditions  which  is  associated  with  secondary 
dyplasia.  This  included  7  cases  with  haematinic 
deficiencies,  be  it  iron,  folate,  vitamin  B12  or  a 
combination of these. Also included were 4 patients 
with systemic sepsis, 4 with auto-immune disease, 3 
each  with  chronic  renal  failure  and  chronic 
inflammatory diseases, 2 with thyroid disease and 1 
with  liver  cirrhosis.  Three  of  the  patients  were 
admitted  with  haematological  disorders  involving 
either platelets or red cells.
Bone  Marrow  Morphology: Various  dysplastic 
features could be noted in all cell lines (Table 2). 
Of note was the presence of trilineage dysplasia in 
one third of the patients, and bilineage dysplasia in 
another  third.  Dysplasia  was  noted  in  only  one 
lineage in 26% of cases and no dysplastic features 
were noted in 9%. Blast counts were not increased 
in  any  of  the  HIV-1  positive  patients,  and 
monocytosis was a rare finding. Although dysplasia 
was a frequent finding, it could not be demonstrated 
in  more  than  10%  of  the  myeloid  lineage,  and 
therefore did not meet the WHO diagnostic criteria 
for primary myelodysplastic syndrome.
Flow  Cytometric  Analysis:  In  the  HIV-1  positive 
study  group,  the  average  CD10  expression  on 
granulocytes were 18.4% (SD of 15.83) compared 
to the HIV-1 negative group with levels of 37.1% 
(SD 21.2) (Figure 3). In the HIV-1 positive group 
113/117  (96.6%)  patients  had  a  total  CD10 
expression of less than 50%, in contrast to  22/29 
(75.9%)  the  HIV-1  negative  group  (table 
1)(p<0.0001). A left shift in the granulocyte lineage 
could be demonstrated in <30% of cases. Exclusion 
of these left-shifted cases did not have a statistically 
significant  impact  on  the  data,  increasing  the 
average CD10 expression to 18.5%. No correlation 
between  CD10  granulocyte  percentage  and  CD4 
counts (as a marker for HIV-1 disease progression) 
could  be  demonstrated  in  the  HIV-1  positive 
population (p>0.34). 
Table 2. Dysplastic features in HIV-1 infected patients.
Dysplastic Features Absolute
n=70 (percentage)
Bone marrow
cellularity
Hypercellular 31 (44%)
Normocellular 35 (50%)
Hypocellular 5 (6%)
Granulocytic 
Lineage
Left shift 21 (30%)
Giant Metamyelocytes 33 (47%)
Monocytosis 1 (1%)
Hypogranularity 3 (4%)
Hyposegmentation* 24 (34%)
Hypersegmentation 9 (13%)
Erythroid lineage
Red cell dysplasia§ 57 (81%)
Macronormoblasts 11 (16%)
Megaloblasts 25 (36%)
Multinuclear erythroid 
cells 14 (20%)
Megakaryocytic 
lineage
Micromegakaryocytes 4 (6%)
Atycal nuclear 
configurations 26 (37%)
Sideroblasts (n=46)
Decreased 35 (22%)
Normal 1 (2%)
Incresed/pathologically 
overloaded 10 (76%)
*Hyposegmentation includes Pseudo-Pelger-Huet forms and 
ring forms
§Red cell Dysplasia includes uneven haemoglobinization, 
ragged cytoplasm and intercytoplasmic bridgingMedit J Hemat Infect Dis 2010; 2(3); Open Journal System 
Figure 3. CD10 expression depicted as a Box and Whisker plot
Discussion: Changes in bone marrow morphology 
associated with HIV-1 infection has been evaluated 
by various authors.
1,5,8,28 These studies showed that 
certain  findings  are  common  to  both  HIV
MDS.  These  include  increased  bone  marrow 
cellularity,  left  shift  in  granulocytes,  presence  of 
giant band cells and megaloblastoid changes in the 
erythroid lineage, consistent with the findings in the 
current  study.  Macrocytosis  can  also  be  present 
especially  secondary  to  drugs  administered  in  the 
treatment  of  HIV-1.  Findings  found  in  primary 
MDS,  in  contrast  to  HIV-1  dysplasia  include  an 
increase  in  blast  cells, hypogranularity as well  as 
hyper- or  hyposegmentation  of  granulocytes  and 
micromegakaryocytes  with  atypical  lobulation,
but  the  blast  counts  were  not  elevated.  These 
finding were not in keeping with the current
as  hypogranularity,  hyposegmentation, 
hypersegmentation  and  the  dysplastic  features  in 
megakaryocytes  were  relatively  common  among 
our HIV-1 positive population. These findings have 
been  cited  as  useful  in  delineating  between  these 
two  conditions,  however,  changes  may  be  subtle. 
Depending  on  the  different  subclasses  of  primary 
; Open Journal System 
CD10 expression depicted as a Box and Whisker plot
Changes in bone marrow morphology 
1 infection has been evaluated 
These studies showed that 
certain  findings  are  common  to  both  HIV-1  and 
MDS.  These  include  increased  bone  marrow 
cellularity,  left  shift  in  granulocytes,  presence  of 
egaloblastoid changes in the 
erythroid lineage, consistent with the findings in the 
current  study.  Macrocytosis  can  also  be  present 
especially  secondary to  drugs  administered  in  the 
1.  Findings  found  in  primary 
splasia  include  an 
increase in  blast  cells,  hypogranularity as  well  as 
or  hyposegmentation  of  granulocytes  and 
micromegakaryocytes  with  atypical  lobulation,
23
but  the  blast  counts  were  not  elevated.  These 
finding were not in keeping with the current study, 
as  hypogranularity,  hyposegmentation, 
hypersegmentation  and  the  dysplastic  features  in 
megakaryocytes  were  relatively  common  among 
1 positive population. These findings have 
been  cited  as  useful  in  delineating between  these 
however,  changes  may  be  subtle. 
Depending  on  the  different  subclasses of  primary 
MDS,  degrees  of  dysplasia  may  also  vary.
Therefore, distinguishing morphologically between 
primary  and  secondary  dysplasia  can  be  very 
troublesome. 
For  all  these  reasons, 
underlying cause of dysplasia should be approached 
as  a  multidisciplinary  work
considered  diagnostic,  cytogenetic  analysis 
typically contributes to only 40% of cases, showing 
a  variety  of  abnormalties.
4 Consequently,  scoring 
systems have been advocated for use in diagnosis to 
improve sensitivity and specificity of diagnosis
Various  flow  cytometric  parameters  have  been 
evaluated as useful diagnostic indicator
including use of CD10 expression on granulocytic 
cells.
21
Expression  of  CD10  has  been  examined  as  a 
marker  of  granulocyte  maturation  in  various 
studies,
12,14 as  it  is  expressed  by  terminally 
differentiated  neutrophils.
25 Levels  have  been 
evaluated  by  numerous  authors,  showing  reduced 
levels on granulocytes varying from 20 to 70%
depending  on  the  subtype  of  MDS.  Secondary 
dysplastic  changes  can  occur  due  to  various 
MDS,  degrees  of  dysplasia  may  also  vary.
23
Therefore, distinguishing morphologically between 
primary  and  secondary  dysplasia  can  be  very 
For  all  these  reasons,  establishing  the 
underlying cause of dysplasia should be approached 
as  a  multidisciplinary  work-up.  Although 
considered  diagnostic,  cytogenetic  analysis 
typically contributes to only 40% of cases, showing 
Consequently,  scoring 
ystems have been advocated for use in diagnosis to 
improve sensitivity and specificity of diagnosis.
4,16
Various  flow  cytometric  parameters  have  been 
evaluated as useful diagnostic indicators in  MDS, 
including use of CD10 expression on granulocytic 
Expression  of  CD10  has  been  examined  as  a 
marker  of  granulocyte  maturation  in  various 
as  it  is  expressed  by  terminally 
Levels  have  been 
d  by  numerous  authors,  showing  reduced 
levels on granulocytes varying from 20 to 70%,
11
depending  on  the  subtype  of  MDS.  Secondary 
dysplastic  changes  can  occur  due  to  various Medit J Hemat Infect Dis 2010; 2(3); Open Journal System 
conditions  and  should  be  excluded  before  the 
diagnosis of MDS can be considered.
3 With specific 
relevance to HIV-1 positive patients, long term use 
of  zidovudine  (AZT)  has  been  shown  to  induce 
dysplasia  in  mouse  studies.
2 However  use  of 
gancyclovir  and  trimethoprim-sulfamethoxaxole 
(standard prophylactic antibiotic used according to 
the South African guidelines) have not been shown 
to induce dysplasia in vivo.
23 The HIV-1 negative 
group also included some patients with other causes 
of secondary dysplasia.
31 This again correlates with 
the  finding  of  reduced  CD10  expression  in  this 
population as well,  where almost 76% of patients 
had levels below 50%. In  light of  these findings, 
decreased  CD10  expression  may  correlate  with 
myeloid  dysplasia,  not  only  in  primary,  but  also 
secondary dysplastic conditions.
Decreased  CD10  expression  has  been 
associated  with  increased  susceptibility  to 
infections,  likely  due  to  its  role  in  neutrophil 
chemotaxis  and  coordination  of  the  inflammatory 
response.
22 This becomes clinically evident amongst 
neonates,  patients  with  burns  and  those  with 
systemic sepsis, all of which have been shown to 
have  both  reduced  CD10  expression  on  their 
granulocytes, and a degree of immunosuppression.
6
The  clinical  implications  of  the  reduced  CD10 
expression noted in HIV-1 positive patients remain 
unknown. 
The  diagnostic  utility  of  FCM  has  not  been 
evaluated  in  HIV  positive  patient’s  bone  marrow 
samples. The interrelationship between the presence 
of dysplasia and the effect on the function of the 
bone  marrow  has  also  not  been  studied.  In  this 
study, HIV-1 positive patients showed a significant 
reduction in CD10 expression, with 96.6% of the 
patients showing expression below 50%. This calls 
into doubt the use of this marker as an adjunct in the 
diagnosis of MDS. 
Conclusion: Flow cytometry is a useful adjunct in 
the  diagnosis  of  MDS.  Although  a single antigen 
abnormality cannot be used in isolation to diagnose 
MDS,  it  remains  of  paramount  importance  to 
evaluate the merit  of  each antigen within  clinical 
context. Utility of specific markers should however 
be  carefully  evaluated  as  causes  of  secondary 
dysplasia may also elicit similar immunophenotypic 
abnormalities,  currently  advocated  as  markers 
specific  for  primary  myelodysplasia.  A  full 
understanding  needs  to  be  gained  on 
immunophenotypic changes associated with various 
stages of HIV-1 infection, to so facilitate use of this 
diagnostic  adjunct  in  this  patient  population.  The 
impact of  these aberrancies needs  to be clinically 
correlated  with  the  degree  of  immunological 
dysfunction.
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